As it scales up for future business growth in line with its five-year strategy
Clinigen Group, a specialist pharmaceutical products business headquartered in the UK, has made organisational changes to prepare for scale-up in line with its five-year growth strategy and to support recent organic growth and the integration of two new products in its Specialty Pharmaceuticals business.
Under the new structure, Shaun Chilton, formerly the Chief Operating Officer in charge of the Clinigen CTS (Clinical Trial Supply) and Clinigen GAP (Global Access Programs) businesses has been appointed Chief Operating Officer for the Group and will add management of the Specialty Pharmaceutical business to his responsibilities. He will be supported in this role by the appointment of new Senior Vice Presidents to run each of these businesses.
Mark Corbett, formerly Vice President of GAP, will lead Clinigen GAP. Lorann Morse will become Senior Vice President of Clinigen CTS (Clinical Trial Supply) having joined Clinigen from Myoderm where she was Director of Client Services. She will be based in Philadelphia and brings regional expertise and insight to the CTS business.
David Bryant will move from his role as Business Development Director to lead Clinigen SP (Specialty Pharmaceuticals), while Anton Jenkins, previously COO of Clinigen SP, has been appointed as Business Development Director, performing a key role that is focused on the further in-licensing and acquisition of new products.
Peter George, Chief Executive of Clinigen Group said: ‘Over the past three years, we have seen significant organic growth of CTS and GAP and the expansion of our product portfolio with the acquisition of Cardioxane from Novartis and in-licensing of VIBATIV from Theravance.
‘Now is a logical time for us to ensure we have the right infrastructure and people in place to be able to scale-up further for future growth and achieve our ambitious plans.’